Photo from archive.org
Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination… Click to show full abstract
Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an alternative for patients whose tumors do not respond to standard therapy.
Keywords:
triggers responses;
indoximod combo;
combo triggers;
responses melanoma
Journal Title: Cancer discovery
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!